Molecular Mechanism of Nishamalaki as Rasayana in Diabetes Mellitus

IF 0.1 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
Sridhanya Venkataramanan, Rajeshwari V Kamat, Sanjay Ugare
{"title":"Molecular Mechanism of Nishamalaki as Rasayana in Diabetes Mellitus","authors":"Sridhanya Venkataramanan, Rajeshwari V Kamat, Sanjay Ugare","doi":"10.47552/ijam.v15i2.4552","DOIUrl":null,"url":null,"abstract":"Diabetes mellitus, a chronic non-communicable disorder, is on the rise in developing countries. In Ayurveda, a similar condition called Madhumeha is attributed to Dhatu kshaya (Emaciation) and Dosha avarana (occlusion of humoral factors). Rasayana therapy, involving herbal formulations like Nishamalaki, is recommended to strengthen the body's major structural components (dhatus), boost immunity, and promote longevity. Nishamalaki, a combination of Haridra (Curcuma longa Linn.) and Amalaki (Phyllantus emblica Linn.), exhibits antioxidant, anti-inflammatory, and lipid-reducing properties. It holds potential as a preventive measure to enhance the Quality of Life. The aim of this study was to validate the rejuvenation property of Nishamalaki in Diabetes mellitus using an insilico approach. Through tools such as SwissADME, SwissTargetPrediction, and Therapeutic Target Database (TTD), bioavailable components of Nishamalaki and Diabetes were analyzed, and a network was created using CytoScape. The results of the study identified two key compounds, Ellagic acid and Corilagin, which significantly modulate IGF1R and PTPN1, respectively, in Diabetes mellitus. These findings offer valuable insights into the potential therapeutic benefits of Nishamalaki in managing Diabetes mellitus and warrant further research and exploration in this area. ","PeriodicalId":13751,"journal":{"name":"International Journal of Ayurvedic Medicine","volume":null,"pages":null},"PeriodicalIF":0.1000,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Ayurvedic Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47552/ijam.v15i2.4552","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Diabetes mellitus, a chronic non-communicable disorder, is on the rise in developing countries. In Ayurveda, a similar condition called Madhumeha is attributed to Dhatu kshaya (Emaciation) and Dosha avarana (occlusion of humoral factors). Rasayana therapy, involving herbal formulations like Nishamalaki, is recommended to strengthen the body's major structural components (dhatus), boost immunity, and promote longevity. Nishamalaki, a combination of Haridra (Curcuma longa Linn.) and Amalaki (Phyllantus emblica Linn.), exhibits antioxidant, anti-inflammatory, and lipid-reducing properties. It holds potential as a preventive measure to enhance the Quality of Life. The aim of this study was to validate the rejuvenation property of Nishamalaki in Diabetes mellitus using an insilico approach. Through tools such as SwissADME, SwissTargetPrediction, and Therapeutic Target Database (TTD), bioavailable components of Nishamalaki and Diabetes were analyzed, and a network was created using CytoScape. The results of the study identified two key compounds, Ellagic acid and Corilagin, which significantly modulate IGF1R and PTPN1, respectively, in Diabetes mellitus. These findings offer valuable insights into the potential therapeutic benefits of Nishamalaki in managing Diabetes mellitus and warrant further research and exploration in this area. 
Nishamalaki 作为 Rasayana 治疗糖尿病的分子机制
糖尿病是一种慢性非传染性疾病,在发展中国家呈上升趋势。在阿育吠陀学中,类似的病症被称为 "Madhumeha",归因于 Dhatu kshaya(消瘦)和 Dosha avarana(体液因素闭塞)。建议采用 Rasayana 疗法(包括 Nishamalaki 等草药配方)来增强人体的主要结构成分(Dhatus)、提高免疫力并促进长寿。Nishamalaki 是 Haridra(莪术)和 Amalaki(金莲花)的组合,具有抗氧化、消炎和降脂的功效。它具有作为预防措施提高生活质量的潜力。本研究的目的是利用一种内模拟方法验证 Nishamalaki 对糖尿病的恢复活力特性。通过 SwissADME、SwissTargetPrediction 和 Therapeutic Target Database (TTD) 等工具,分析了 Nishamalaki 和糖尿病的生物可用成分,并使用 CytoScape 创建了一个网络。研究结果发现了两种关键化合物--鞣花酸和柯里拉京,它们分别能显著调节糖尿病患者的 IGF1R 和 PTPN1。这些发现为了解 Nishamalaki 在治疗糖尿病方面的潜在疗效提供了宝贵的见解,值得在这一领域开展进一步的研究和探索。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Journal of Ayurvedic Medicine
International Journal of Ayurvedic Medicine MEDICINE, RESEARCH & EXPERIMENTAL-
自引率
50.00%
发文量
87
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信